Efficacy study of eltrombopag in the treatment of systemic lupus erythematosus with refractory thrombocytopenia
10.3760/cma.j.cn141217-20241231-00388
- VernacularTitle:艾曲波帕治疗系统性红斑狼疮伴原发免疫性血小板减少症的疗效研究
- Author:
Zhuoyu LI
1
;
Xue WU
1
;
Qianxi XU
1
;
Mengsi MA
1
;
Lijun WU
1
Author Information
1. 新疆维吾尔自治区人民医院风湿免疫科, 乌鲁木齐 830001
- Publication Type:Journal Article
- Keywords:
Lupus erythematosus, systemic;
Immune thrombocytopenic purpura;
Eltrombopag;
Clinical efficacy
- From:
Chinese Journal of Rheumatology
2025;29(9):776-780
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluated the efficacy and safety of eltrombopag in patients with systemic lupus erythematosus (SLE)-related refractory immune thrombocytopenia (ITP).Methods:Nine patients with severe SLE-associated refractory ITP were recruited the People's Hospital of Xinjiang Uygur Automomous Region from Septermber 2021 to February 2024 and received eltrombopag 50 mg orally daily for 1 month; basic patient information, platelet counts, other laboratory parameters and adverse events were recorded. Normally distributed continuous data were expressed as mean±standard deviation ( Mean±SD) and compared using paried samples t-test; non-normally distributed data were presented as median (interquartile range) [ M( Q1, Q3)]; categorical variables were described as n (%). Results:Eight participants (88.9%) completed the study, and at 1 month, five patients showed significant improvement in subcutaneous bleeding and erythema of the skin and mucous membranes, and three patients showed significant relief of joint and muscle involvement, and the patients′ platelet counts were (16.9±9.6)×10 9/L before treatment and increased to (114.0±53.9)×10 9/L. Differences in platelet levels before and after treatment in intergroup comparisons ( t=-4.881 , P=0.002), of which 4 patients achieved complete remission of platelet involvement, 3 patients achieved partial remission of platelet involvement, 4 cases were significantly efficacious and 3 cases efficacious. Follow-up data showed that platelet counts remained normal with no significant adverse events and one patient discontinued the study after 2 weeks of eltrombopag due to abnormal blood counts. Conclusion:Eltrombopag may be a promising new option for patients with SLE-associated refractory ITP with satisfactory remission rates, but large sample studies are needed for validation.
